Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

 

The Celiac Drugs Market, in the next 10 years, is expected to substantiate. Hospital decision support solutions are being floated, and the status quo is expected to stay the same even going forward. Herein, value propositions are made to the society on the whole and patients in particular by the government, private insurance companies, and social security organizations working in unison. As such, the healthcare industry is expected to witness a good number of clinical outcomes in the forthcoming period.

Celiac disease, also known as celiac sprue or gluten-sensitive enteropathy, is a genetic autoimmune disorder caused due to the body’s inability to process gluten that causes damage to the small intestine. Gluten, a protein found in wheat, barley, and rye, can damage the lining of the small intestine which makes it difficult for the body to absorb nutrients such as iron, fat, calcium, and folate.

The immune system mistakes substances inside gluten to be a threat to the body and attacks them, in turn, causing damage to the bowel surface and hampering the body’s ability to absorb nutrition. Digestion problems, dermatitis herpetiformis, abdominal pain, weight loss, musculoskeletal problems, aphthous ulcers, iron deficiency, stunted growth, tingling sensation in the leg, and missed menstrual cycles are some of the symptoms of celiac disease.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/4095

The disease can lead to various complications and health problems such as miscarriage or infertility, intestinal cancer, osteoporosis, seizures, gall bladder malfunction, neurological manifestation of the disease, stunted growth in children, and birth defects.

Celiac disease can also lead to various autoimmune diseases such as lupus, thyroid disease, Sjögren’s syndrome, type 1 diabetes, and rheumatoid arthritis. It is difficult to diagnose celiac disease in the initial stages as its symptoms are similar to those of other diseases. Various sensitive and selective blood tests such as anti-tissue transglutaminase antibodies with or without IgA level and IgA anti-endomysial antibodies are used to screen the disease.

These tests detect auto-antibodies which are present in higher-than-normal levels in the blood of patients who have celiac disease. If the tests show positive results for celiac disease, a small bowel biopsy is done to confirm the diagnosis and determine the level of damage to the lining of the intestine.

Request for Table of Content@ https://www.persistencemarketresearch.com/toc/4095

Approximately, 6 million people suffer from celiac disease in the U.S and Europe. Currently, no drugs, vaccines, or surgical treatments are available for the disease. Gluten free diet is recommended to control the symptoms and prevent long term effects of celiac disease. Immune-modulatory and other therapies are used for the treat the symptoms of celiac disease.

North America dominates the global market for celiac drugs due to rising incidence of celiac disease and lack of treatment options in the region. Asia is expected to show high growth rates in the next five years in global celiac drugs market, with China and India being the fastest growing markets in the Asia-Pacific region.

The key driving forces for the celiac drugs market in developing countries are the large pool of patients, increasing awareness about the disease, and rising government funding in the region.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/4095  

Increase in healthcare expenditure, changing lifestyles, increasing awareness about healthcare, and increasing number of initiatives by various governments and government associations are some of the key factors driving the growth of the global celiac drugs market. However, complex regulatory frameworks for the approval of drugs in most countries is a major restraint on the growth of the global celiac drugs market.

Innovation of drugs to treat celiac disease would help develop opportunities for the global celiac disease market. The major companies operating in the global celiac drugs market are Alvine Pharmaceuticals, Inc., Alba Therapeutics Corporation, ImmusanT, and the Institute for Protein Design.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts